Escitalopram
Is It Right for You?
A complete guide to Escitalopram — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Escitalopram?
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) – one of the most widely prescribed classes of antidepressant medication in the world. It is used to treat depression and a range of anxiety disorders and is consistently ranked among the most effective and best-tolerated antidepressants available in primary care. In the UK, escitalopram is recommended as a first-line pharmacological treatment by the National Institute for Health and Care Excellence (NICE) for both depression and generalised anxiety disorder.
Escitalopram is the S-enantiomer of citalopram – meaning it is the pharmacologically active component of the older antidepressant citalopram, isolated and used alone. This refinement gives escitalopram a more selective and potent action at the serotonin transporter than citalopram, allowing effective treatment at lower doses with a cleaner side effect profile. Large-scale meta-analyses comparing antidepressants have consistently placed escitalopram at or near the top of rankings for both efficacy and tolerability among SSRIs.
Escitalopram is available in tablet and oral drop solution forms and is suitable for adults and adolescents aged 12 years and above for certain indications. It is available generically and under the brand name Cipralex in the UK.
Escitalopram is a prescription-only medication in the UK. A licensed clinician must assess your symptoms and medical history before it can be prescribed – which can now be done quickly and conveniently through a telehealth consultation.
What Conditions Is Escitalopram Used For?
Escitalopram is licensed and widely used for a range of mental health conditions:
first-line pharmacological treatment for moderate to severe depression; reduces core symptoms including persistent low mood, loss of interest and pleasure (anhedonia), fatigue, hopelessness, disturbed sleep, and impaired concentration.
one of the most evidence-based treatments for GAD; reduces excessive, persistent worry and the associated physical symptoms of anxiety including muscle tension, fatigue, and sleep disturbance.
reduces the frequency and severity of panic attacks and the anticipatory anxiety and avoidance behaviours associated with panic disorder.
reduces fear and avoidance in social situations, improving social and occupational functioning.
reduces the frequency, intensity, and distress of obsessions and compulsions when used in conjunction with psychological therapies such as cognitive behavioural therapy (CBT).
used to reduce hyperarousal, re-experiencing symptoms, avoidance, and associated depression in PTSD.
Unlike medications that produce effects within hours, escitalopram typically requires 2 to 6 weeks of consistent daily use before meaningful improvements in mood or anxiety are noticed. Full therapeutic benefit may take 8 to 12 weeks. Side effects – particularly nausea and initial anxiety – often precede therapeutic benefits in the early weeks. It is important not to stop escitalopram prematurely due to the delay in effect or early side effects. Always discuss any concerns with your clinician before making changes to your medication.
How Does Escitalopram Work?
Escitalopram belongs to the selective serotonin reuptake inhibitor (SSRI) class and works by increasing the availability of serotonin – a key neurotransmitter involved in mood regulation, anxiety, sleep, appetite, and cognitive function – in the synaptic cleft between nerve cells.
Under normal physiological conditions, after serotonin is released from a presynaptic nerve terminal and activates receptors on adjacent neurons, it is transported back into the releasing neuron via the serotonin transporter (SERT) – a process known as reuptake. This mechanism terminates serotonergic signalling and recycles serotonin for future use.
Escitalopram selectively and potently binds to the serotonin transporter, blocking reuptake and causing serotonin to accumulate in the synapse. The resulting prolonged and enhanced serotonergic neurotransmission gradually normalises the dysregulated neural circuits associated with depression and anxiety.
Escitalopram's selectivity for the serotonin transporter is exceptionally high – it has minimal affinity for noradrenaline transporters, dopamine transporters, histamine receptors, muscarinic receptors, or adrenergic receptors. This high selectivity is what gives escitalopram its particularly clean side effect profile compared to older antidepressants and even some other SSRIs, which have more off-target receptor effects.
A distinctive pharmacological feature of escitalopram is its ability to bind to an allosteric site on the serotonin transporter in addition to the primary binding site. This dual binding increases the drug's overall inhibitory effect on serotonin reuptake and contributes to its greater potency compared to citalopram and other SSRIs at equivalent doses.
The therapeutic effects of escitalopram are not simply the result of the immediate increase in synaptic serotonin. The antidepressant and anxiolytic benefits emerge over weeks as sustained serotonergic signalling triggers downstream neuroadaptive changes – including increased expression of brain-derived neurotrophic factor (BDNF), neuroplasticity, and synaptic remodelling in circuits involving the prefrontal cortex, hippocampus, and amygdala. This delayed neuroadaptation explains the characteristic lag of several weeks before therapeutic effects are fully realised.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Escitalopram can be taken with or without food. Taking it with a meal may reduce the likelihood of nausea, which is one of the most common early side effects. It can be taken at any time of day, though consistency is important.
Take escitalopram at the same time each day – either morning or evening, depending on which suits you best and helps you remember. Some patients prefer morning dosing if they find the medication slightly activating; others prefer evening dosing if they experience mild drowsiness. Discuss with your clinician which timing is most appropriate for you.
Start at a low dose. Escitalopram is typically started at 5 to 10 mg and increased after 1 to 2 weeks if tolerated and if a higher dose is clinically indicated. Gradual titration reduces the intensity of early side effects, particularly nausea and initial increased anxiety.
Be patient. Most patients do not feel the full benefit of escitalopram for 4 to 12 weeks. A common reason for treatment failure is stopping the medication too early, before therapeutic effects have had time to develop. Persist through the initial adjustment period, using your clinician as a source of support and monitoring.
Do not stop escitalopram abruptly. Stopping suddenly can cause discontinuation syndrome – symptoms including dizziness, nausea, flu-like feelings, electric shock sensations ("brain zaps"), irritability, and emotional instability. Always taper the dose gradually over several weeks under medical supervision when stopping treatment.
Oral drops should be measured carefully using the provided dropper and mixed with water, orange juice, or apple juice (not carbonated drinks). Each drop contains 1 mg of escitalopram.
Side Effects of Escitalopram
Side effects are most common in the first 1 to 2 weeks of treatment and often diminish significantly as the body adjusts. Escitalopram has one of the most favourable tolerability profiles of any antidepressant. Serious side effects are uncommon but require prompt medical attention.
- Nausea (most common early side effect; usually resolves within 1–2 weeks)
- Headache
- Dry mouth
- Increased sweating (including night sweats)
- Insomnia or sleep disturbance
- Fatigue or drowsiness
- Diarrhoea
- Dizziness
- Sexual dysfunction – reduced libido, delayed ejaculation, or difficulty reaching orgasm
- Appetite changes
- Tremor (mild)
- Increased anxiety or agitation in the first 1–2 weeks (paradoxical early effect that typically resolves)
- Suicidal thoughts or self-harm ideation – particularly in children, adolescents, and young adults in the early weeks of treatment; any new or worsening thoughts of suicide or self-harm require immediate medical attention
- Serotonin syndrome – a rare but potentially life-threatening condition caused by excessive serotonergic activity; symptoms include agitation, confusion, rapid heart rate, high temperature, muscle twitching, excessive sweating, and tremor; most likely when escitalopram is combined with other serotonergic drugs
- QT prolongation and cardiac arrhythmia – escitalopram has a dose-dependent effect on the cardiac QT interval; the maximum doses (20 mg in adults, 10 mg in elderly) are set partly to limit this risk; seek immediate attention for palpitations, irregular heartbeat, or fainting
- Hyponatraemia (low sodium) – particularly in elderly patients; symptoms include headache, confusion, weakness, and in severe cases seizures or loss of consciousness
- Severe allergic reaction – hives, facial swelling, difficulty breathing, collapse; rare
- Abnormal bleeding – SSRIs reduce platelet aggregation, increasing the risk of bleeding, particularly gastrointestinal bleeding when combined with NSAIDs or anticoagulants
- Mania or hypomania – may unmask or trigger manic episodes in patients with undiagnosed or known bipolar disorder
- Seizures – rare; more likely in patients with a history of epilepsy or at high doses
Clinical trials have shown a small but statistically significant increase in suicidal thoughts and behaviours in children, adolescents, and young adults (up to age 25) in the early weeks of antidepressant treatment. Patients and their families or carers should be alert to any new or worsening thoughts of self-harm, unusual mood changes, agitation, or restlessness – particularly in the first 4 weeks and after any dose change. If these occur, seek immediate medical attention. This does not mean antidepressants cause suicide, but close monitoring during the early treatment period is essential.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting escitalopram.
Combining escitalopram with MAOIs can cause potentially fatal serotonin syndrome. Escitalopram must not be started within 14 days of stopping a non-reversible MAOI (or 1 day for moclobemide). An MAOI must not be started within 7 days of stopping escitalopram. This combination is absolutely contraindicated.
Escitalopram has a dose-dependent effect on QT prolongation. Combining it with other QT-prolonging medications significantly raises the risk of serious cardiac arrhythmias. This combination should be avoided or only used under close cardiac monitoring. The maximum dose of escitalopram (20 mg) must not be exceeded when QT-prolonging drugs are co-prescribed.
Combining escitalopram with other serotonergic medications significantly increases the risk of serotonin syndrome. St John's Wort – an over-the-counter herbal remedy often used for low mood – can cause serotonin syndrome when combined with SSRIs and must be avoided entirely during escitalopram treatment.
SSRIs reduce platelet aggregation, and combined use with anticoagulants or antiplatelet drugs significantly increases bleeding risk. INR should be monitored in patients on warfarin when escitalopram is started or stopped. Concurrent NSAID use should be avoided where possible due to the substantially increased risk of gastrointestinal bleeding.
Concurrent use of NSAIDs with escitalopram significantly increases the risk of gastrointestinal bleeding. If NSAIDs are necessary in a patient taking escitalopram, a proton pump inhibitor should be co-prescribed for gastroprotection.
These medications inhibit the CYP2C19 enzyme responsible for metabolising escitalopram, potentially doubling escitalopram plasma levels. The escitalopram dose may need to be halved in patients taking these medications. Inform your clinician or pharmacist if you take any acid-reducing medication.
Carbamazepine may reduce escitalopram plasma levels through CYP3A4 induction, potentially reducing efficacy. Dose adjustment may be required. Conversely, escitalopram may increase carbamazepine levels in some patients.
Escitalopram may increase plasma levels of some antipsychotics and adds to QT prolongation risk. Caution and monitoring are required when these combinations are necessary.
Escitalopram does not have a clinically significant pharmacokinetic interaction with alcohol, but alcohol is a central nervous system depressant that worsens the symptoms of depression and anxiety. Regular alcohol consumption is likely to undermine the therapeutic benefit of escitalopram and is strongly discouraged during treatment.
Important Warnings
Serotonin syndrome is a rare but potentially life-threatening emergency caused by excessive serotonergic activity, most commonly occurring when escitalopram is combined with other serotonergic drugs. Symptoms develop rapidly and include agitation, confusion, restlessness, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity or twitching, high temperature, and excessive sweating. If these symptoms develop, stop escitalopram and seek emergency medical attention immediately. Inform all treating clinicians and pharmacists that you are taking escitalopram.
The combination of escitalopram with monoamine oxidase inhibitors is absolutely contraindicated due to the risk of fatal serotonin syndrome. Mandatory washout periods must be observed between stopping an MAOI and starting escitalopram, and vice versa. Always inform every clinician, dentist, and pharmacist you see that you are taking escitalopram.
Escitalopram produces a dose-dependent prolongation of the cardiac QT interval, which can predispose to Torsades de Pointes – a serious and potentially fatal ventricular arrhythmia. This risk is increased at doses above 20 mg (which should never be exceeded), in patients with pre-existing QT prolongation, hypokalaemia, hypomagnesaemia, bradycardia, or those taking other QT-prolonging medications. Patients with known cardiac conditions should have an ECG before starting escitalopram and during treatment. Seek immediate help if palpitations, fainting, or irregular heartbeat develop.
Stopping escitalopram abruptly or missing several consecutive doses can cause discontinuation syndrome, characterised by dizziness, nausea, flu-like symptoms, sensory disturbances ("brain zaps"), irritability, and emotional instability. These symptoms are uncomfortable but not dangerous. Always taper escitalopram gradually over several weeks under medical supervision. The taper schedule should be individualised, particularly for patients who have been on higher doses or longer-term treatment.
Escitalopram, like all SSRIs, can cause syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to low blood sodium (hyponatraemia). This is most likely in elderly patients, those taking diuretics, and those with low fluid or salt intake. Symptoms include headache, difficulty concentrating, confusion, weakness, and in severe cases, seizures or loss of consciousness. Sodium levels should be checked if these symptoms develop, particularly in elderly patients starting escitalopram.
Escitalopram, like all antidepressants, can trigger manic or hypomanic episodes in patients with bipolar disorder by shifting mood polarity. If you have a personal or family history of bipolar disorder, inform your clinician before starting escitalopram. Antidepressants in bipolar disorder should only be prescribed alongside a mood stabiliser and under specialist supervision.
Escitalopram inhibits platelet serotonin reuptake, impairing platelet aggregation and increasing the risk of abnormal bleeding. This risk is substantially increased when escitalopram is combined with NSAIDs, aspirin, or anticoagulants. Inform your clinician and any other healthcare provider – including surgeons and dentists – that you are taking escitalopram before any procedure.
Escitalopram is one of the better-studied SSRIs in pregnancy. The decision to use escitalopram during pregnancy involves a careful assessment of the risks of untreated depression or anxiety against potential medication risks. Use in late pregnancy has been associated with neonatal adaptation syndrome (transient symptoms in the newborn) and, rarely, persistent pulmonary hypertension of the newborn (PPHN). Escitalopram passes into breast milk; sertraline is more commonly preferred during breastfeeding due to a larger evidence base, though escitalopram is considered an acceptable alternative. Always discuss with your clinician if you are pregnant, planning a pregnancy, or breastfeeding.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Escitalopram FAQs
Yes. A licensed clinician can assess your symptoms and mental health history via a telehealth consultation and prescribe escitalopram if it is clinically appropriate. Prescriptions are typically sent to your preferred pharmacy the same day, often within minutes of your consultation.
Escitalopram typically takes 2 to 6 weeks before meaningful improvements in mood or anxiety are noticed. Full therapeutic benefit may take 8 to 12 weeks. Some patients notice early improvements in sleep quality, appetite, and energy before mood itself lifts. It is important to continue taking escitalopram consistently and not to stop due to a perceived lack of effect in the first few weeks.
Escitalopram is the active S-enantiomer of citalopram – in other words, citalopram is a mixture of two mirror-image molecules (R and S forms), and escitalopram is the pharmacologically active S-form isolated and used alone. Escitalopram is more potent and selective at the serotonin transporter than citalopram, achieving equivalent or superior therapeutic effects at roughly half the dose. Escitalopram also has a cleaner side effect profile and fewer drug interactions than citalopram. In meta-analyses comparing antidepressants, escitalopram consistently outperforms citalopram on both efficacy and tolerability measures.
Both are SSRIs with broadly similar mechanisms of action and overlapping indications for depression and anxiety disorders. Head-to-head studies and meta-analyses generally show comparable efficacy, with some analyses favouring escitalopram marginally on both efficacy and tolerability. Sertraline has a larger body of safety data in pregnancy and is often preferred during this period. The choice between them often comes down to individual patient factors, clinician preference, prior treatment history, and tolerability. Both are recommended as first-line options in UK guidelines.
No. Escitalopram does not change who you are or alter your personality. Most patients describe feeling more like their usual selves – less burdened by depression or anxiety – rather than feeling different or emotionally blunted. A small proportion of patients on SSRIs describe emotional blunting or reduced emotional range; if this is a concern, discuss it with your clinician as a dose adjustment or change in medication may be appropriate.
Not necessarily. For a first episode of depression, current guidelines recommend continuing escitalopram for at least 6 to 12 months after full symptom resolution to reduce the risk of relapse. For recurrent or chronic depression, longer-term treatment may be appropriate. For anxiety disorders, treatment duration varies. Your clinician will review your treatment regularly and discuss when and how to taper the medication at an appropriate time.
There is no dangerous pharmacokinetic interaction between alcohol and escitalopram, but alcohol is a depressant that worsens depression and anxiety and undermines the therapeutic effects of escitalopram. Regular or heavy drinking is strongly discouraged during treatment. Occasional moderate consumption is unlikely to cause a serious problem for most people, but complete abstinence during the early weeks of treatment – when the medication is establishing itself – is often recommended.
Brain zaps are brief, electric shock-like sensations in the head or body that are one of the most distinctive symptoms of SSRI discontinuation syndrome. They occur because the brain has adapted to the presence of escitalopram and experiences an adjustment period when the drug is withdrawn. They are not dangerous but can be distressing and disorienting. Tapering escitalopram very gradually – sometimes over several months for long-term users – significantly reduces the likelihood and severity of discontinuation symptoms.
Weight changes are possible. In the short term, some patients experience mild appetite reduction and slight weight loss. With longer-term use, modest weight gain is more commonly reported, though this varies considerably between individuals. If weight change is a significant concern, discuss this with your clinician, who can advise on strategies to manage it or consider whether an alternative medication might be more appropriate.
Escitalopram can be used during pregnancy when the benefits outweigh the risks. The decision requires a careful discussion between you and your clinician weighing the risks of untreated depression and anxiety – which can themselves have serious effects on both mother and baby – against the potential effects of medication. Sertraline is often preferred as the first-choice SSRI during pregnancy due to its larger evidence base, but escitalopram is a reasonable alternative. Always inform your clinician if you are pregnant or planning a pregnancy.
Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed one and continue as normal. Do not take a double dose. Try to maintain consistent daily dosing, as missing multiple doses can trigger early discontinuation symptoms and disrupt the stability of your treatment.